Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Acquired Thrombotic Thrombocytopenic Purpura: Clinical Application of Precision Medicine and New Guidelines

In this podcast episode, listen to Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshall Mazepa, MD, answer questions from an audience of healthcare professionals on precision medicine and new guidelines for aTTP.
Ara Metjian, MD
Program Director
Paul Coppo, MD, PhD
Marshall Mazepa, MD
Released: February 1, 2022

In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including:  

  • Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phase
  • Data for caplacizumab in pediatric patients with aTTP
  • Initiating rituximab after completion of plasma exchange
  • International Society on Thrombosis and Haemostasis guideline recommendations against using aspirin
  • Triggers of aTTP episodes aside from infection
  • Effect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapse

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme

Information on this Educational Activity

Program Director

Ara Metjian, MD

Associate Professor
Department of Medicine
University of Colorado
Aurora, Colorado

Ara Metjian, MD, has disclosed that he has received consulting fees from Ablynx/Sanofi Aventis, Genentech, and Shire/Takeda and funds for research support from Ablynx/Sanofi Aventis, Genentech, and Shire/Takeda.

Faculty

Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University
Doctor of Hematology, AP-HP
Paris, France

Paul Coppo, MD, has disclosed that he has received consulting fees from Alexion Pharmaceuticals, Octapharma AG, Roche, Sanofi, Sanofi Aventis, and Takeda and fees for non-CME/CE services from Alexion Pharmaceuticals, Roche, Sandoz, Sanofi Aventis, and Takeda.
Marshall Mazepa, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Marshall Mazepa, MD, has disclosed that he has received fees for non-CME/CE services from Sanofi Aventis.

Program Medium

This program has been made available online.

Related Content

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

person default Justin Arnall, PharmD, BCOP person default Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings